426 Results for "

CDK 2

" in MedChemExpress (MCE) Product Catalog:
Products (426)

426 Results for "CDK 2" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-123772
CAS No.: 865317-30-2
Purity:  99.62%
Synonyms: CP668863
Target:  

CDK

Research Areas:  

Cancer

CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC50s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12445
CAS No.: 1421693-22-2
Purity:  99.18%
Synonyms: CDKI-73; LS-007
Target:  

CDK Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious CDK9 inhibitor, with Ki values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-160701
CAS No.: 2888704-84-3
Synonyms: BLU-222
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Cirtociclib (BLU-222) is an orally active and highly selective CDK2 inhibitor. Cirtociclib disrupts Rb signaling and causes G1 arrest and apoptosis in CCNE1-amplified endometrial cancer cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15275
CAS No.: 582315-72-8
Purity:  99.59%
BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC50 values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N3389
CAS No.: 66056-19-7
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC50 of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N7045
CAS No.: 142796-22-3
Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, Cdk2, Cdc25A), and activate Caspases (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108136A
CAS No.: 145317-11-9
Purity:  98.90%
Synonyms: BIM-X hydrochloride; Ro31-8425 hydrochloride
Target:  

PKC CDK

Bisindolylmaleimide X hydrochloride(Ro 31-8425 hydrochloride, BIM-X hydrochloride) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM. Bisindolylmaleimide X hydrochloride inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X hydrochloride inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X hydrochloride can be used for research on the immune system and cardiovascular diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-162255
CAS No.: 2488073-20-5
Target:  

CDK

Research Areas:  

Cancer

CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC50 = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80076
Synonyms: Cdc2 related protein kinase; CDC28; CDC2A; CDK 2; CDK1; CDK2; CDK2_HUMAN ; CDKN2; MPF; p33(CDK2) antibody;

Host:  

Rabbit

Application:  

WB, ICC/IF, IHC-P, IP, FC

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12843
CAS No.: 189232-42-6
Purity:  98.93%
Target:  

CDK ERK

Research Areas:  

Cancer

Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC50s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC50 of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108359
CAS No.: 237430-03-4
Purity:  99.85%
Synonyms: 9-Nitropaullone; NSC 705701
Target:  

CDK GSK-3 Apoptosis

Research Areas:  

Cancer

Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC50s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis in leukemia cell line .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W011428
CAS No.: 101622-51-9
Target:  

CDK

Research Areas:  

Others Cancer

Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC50=7 μM), CDK/p35 kinase (IC50=3 μM) and ERK1/p44 MAP kinase (IC50=25 μM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80798
Synonyms: CDK2; CDKN2; Cyclin-dependent kinase 2; Cell division protein kinase 2; p33 protein kinase

Host:  

Rabbit

Application:  

WB, IP

Reactivity:  

Human, Hamster, Rat

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103380
CAS No.: 141992-47-4
Purity:  98.58%
Target:  

CDK

Research Areas:  

Cancer

NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC50 of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139725
CAS No.: 2639540-19-3
Purity:  98.47%
Target:  

CDK

Research Areas:  

Metabolic Disease

CDK5-IN-1 is a potent CDK5 inhibitor with an IC50 less than 10 nM. CDK5-IN-1 is greater than 100-fold more active against CDK5 than CDK2. CDK5-IN-1 is used for kidney diseases research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107419
CAS No.: 444723-13-1
Purity:  99.07%
Target:  

CDK Aurora Kinase

Research Areas:  

Cancer

NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-141680
CAS No.: 2756741-90-7
Purity:  99.33%
Target:  

PROTACs CDK

Research Areas:  

Cancer

CPS2 is a first-in-class, highly potent, selective and irreversible PROTAC CDK2 degrader (IC50= 24 nM). CPS2 can be used for the research of acute myeloid leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18930
CAS No.: 2070015-09-5
Target:  

CDK

Research Areas:  

Cancer

NU6300 is a covalent, irreversible and ATP-competitive CDK2 inhibitor with an IC50 value of 0.16 μM. NU6300 can be used for the research of eukaryotic cell cycle- and transcription-related .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-158106
CAS No.: 3047321-53-6
Purity:  99.60%
Synonyms: AZD8421
Target:  

CDK

Research Areas:  

Cancer

Gatsuciclib (AZD8421) is a selective CDK2 inhibitor (IC50 = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9). Gatsuciclib has no significant kinase inhibition outside the CDK family. Gatsuciclib inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. Gatsuciclib can be studied in research for breast cancer and ovarian cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-41076
CAS No.: 1402821-24-2
Target:  

Calcium Channel CDK

Research Areas:  

Neurological Disease

Ca 2+ channel agonist 1 is an agonist of N-type Ca 2+ channel and an inhibitor of Cdk2, with EC50s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction.
loading...
    loading...